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Abstract
Individuals with pulmonary arterial hypertension experience debilitating symptoms and psychological distress which may influence
their cortisol regulation. We describe associations between diurnal salivary cortisol/cortisone levels and quality of life in adults with
pulmonary arterial hypertension. Findings suggest potential clinical utility of cortisol/cortisone assessment as applied to a pulmon-
ary arterial hypertension population.
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To the Editor,
Pulmonary arterial hypertension (PAH) is an uncommon
and unpredictable life-limiting condition.1 There is currently
no cure for PAH, leading to right-sided cardiac failure and
eventually, premature death. Many studies have shown
PAH patients to experience substantial psychological dis-
tress including anxiety, depression and panic.1–3 There is
increased awareness of the need to address psychosocial
aspects including well-being in PAH. We previously pub-
lished a pilot randomised controlled trial demonstrating
the effectiveness of mindfulness-based-stress-reduction to
improve physical functioning and quality-of-life in people
with PAH.1
Due to psychological distress, cortisol production may
become dysregulated via hypothalamic-pituitary-adrenal
axis over activation. This can have a significant impact on
bodily systems; prolonged or repeated stressful experiences
can lead to accumulated physiological dysregulation and
poor health outcomes.4 Dysregulation of cortisol via flatten-
ing of regular diurnal decline has been associated with
poorer health outcomes across a range of physical and
mental health conditions.5 Cortisol awakening response
(CAR), a sudden rise in cortisol levels approximately
30min after awakening, is also associated with physical
and psychological parameters.6
The aim of this current study was to assess levels and
patterning of physiological cortisol and cortisone measured
from diurnal saliva and to examine associations with psy-
chosocial quality of life (QOL) assessed by questionnaire in
adults with PAH.
Participants comprised 19 adult patients (16 years old;
Mage 51.47 years, range 20–88 years; 5 males) recruited from
a pulmonary hypertension clinic, with clinical diagnosis of
PAH (11 simple Eisenmenger [Ventricular septal defect
(VSD) or Atrioventricular septal defect (AVSD)], 2
Double inlet left ventricle with transposed great arteries
(DILV/TGA), 1 Pulmonary atresia with ventricular septal
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defect (PA/VSD), 1 Mustard, 2 postoperative repaired
Congenital heart disease (CHD), 2 unoperated Atrial
septal defect (ASD); 15/19 on disease modifying therapy
[phospodiesterase type 5 A inhibitor or Endothelin receptor
antagonist (PDE5i/ERA)], Pulmonary artery (PA) mean
pressure 67 millimetres of mercury (mmHg)/range=45-
85mmHg), were fluent in English, deemed physically well
enough and had consented to take part. Each participant
received a saliva sampling pack containing nine Salivettes
(Sarstedt, Germany). Saliva was sampled at three intervals
during the day: immediately upon awakening, þ30min after
awakening and immediately before bed. Cortisone and cor-
tisol levels were analysed using ultra performance liquid
chromatography tandem mass spectrometry.
From the three diurnal assessments, four cortisone and
four cortisol indices were calculated: area under the curve
with respect to ground (AUCg) and increase (AUCi),7 awa-
kening response (CAR) (þ30min minus awakening) and
diurnal slope (bedtime minus awakening). A value with
rise of 2.49 nmol/L was considered a CAR.8 For cortisol
slope, a more negative value (steeper slope) indicated greater
diurnal decline. QOL was assessed using the Short Form
Health Survey (SF-36v2), a self-report questionnaire com-
prising two summary scores, each with four health-related
QOL dimensions (Physical Component Score: Physical
Functioning, Role Physical, Bodily Pain, General Health;
Mental Component Score: Vitality, Social functioning,
Role Emotional and Mental Health).9 For raw scores and
normalised scale scores, higher values indicated better
health. Cortisol and cortisone indices were initially assessed
descriptively; diurnal patterning was analysed using
repeated measures ANOVA with Greenhouse-Geisser cor-
rection (sphericity not assumed) followed by pairwise com-
parisons (Bonferroni correction). To examine associations
between baseline cortisone/cortisol and QOL scores, correl-
ations were conducted using Spearman’s rho (2-tailed) and
non-log-transformed values.
As a reference, we compared our data against a salivary
cortisone/cortisol range obtained from 119 mixed age and
gender non-clinical healthy volunteer adults, with early morn-
ing and late evening samples, recruited in a previous study.
Reference ranges (2.5–97.5 percentile) were derived for non-
Gaussian distributions10 which revealed an early morning
range of 3–20nmol/L (cortisol) and 12–45nmol/L (corti-
sone); and a late evening range of <2 nmol/L (cortisol) and
2–18nmol/L(cortisone). Cortisol and cortisone values for our
PAH sample (Fig. 1) were comparable with this reference
range at a level of 88.9% awakening and 83.3% evening (cor-
tisol) and 73.7% awakening and 89.5% evening (cortisone).
There were no extreme values indicated and cases falling mar-
ginally outside of the comparison range could be explained by
requirements of the sampling protocol.
Descriptive analysis of cortisol indices (Fig. 1) showed
PAH patients to have a usual CAR pattern and diurnal
decline with three exceptions: one with a þ30 increase fol-
lowed by a further increase to evening (A); one with a flat
profile across the day (F) and one with a steady decrease
across the day (C). For cortisone indices, all patients showed
expected diurnal patterning with three exceptions: one with
a þ30 increase followed by a flat trajectory to evening (A);
one that was highest at awakening then declined steeply
throughout the day (E); and one which started low and
continued to decline across the day (C). CAR was exhibited
in 61.1% of the sample. In inferential analysis, cortisol
showed significant diurnal change across time points,
F(1,21)¼ 33.83; partial Eta2¼ .67, p< .001. Pairwise com-
parisons revealed significant differences between awakening
to þ30min (p¼ .001), þ30min to evening (p< .001), awa-
kening to evening (p< .001). Cortisone showed significant
diurnal change across time points F(1,27)¼ 41.84; partial
Eta2¼ .70, p< .001. Pairwise comparisons revealed signifi-
cant differences between awakening to þ30 min (p¼ .002),
þ30 min to evening (p< .001) and awakening to evening
(p< .001). There were detectable associations between age
and gender with cortisol/cortisone levels.
A higher level of cortisol at awakening was significantly
associated with higher scores on QOL dimensions of
Physical Functioning (r¼ .59; p¼ .01), General Health
(r¼ .65; p¼ .003) and Vitality (r¼ .68; p¼ .002). Higher cor-
tisol at þ30min was also significantly associated with a
better QOL score on Physical Functioning (r¼ .51;
p¼ .03) and Vitality (r¼ .58; p¼ .012). Higher evening cor-
tisol was significantly associated with poorer health scores
for QOL dimensions of Physical Functioning (r¼.50;
p¼ .03) and Social Functioning (r¼.67; p¼ .002) and
the Physical Component Score (r¼.51; p¼ .028). No sig-
nificant correlations were found between AUCg and CAR
with QOL scores. A significant association was noted
between higher AUCi score and a poorer General Health
dimension score (r¼.49; p¼ .04). Greater cortisol slope
value (flatter slope, less decline from awakening to evening)
was also significantly associated with poorer Physical
Functioning (r¼.67; p¼ .002), lower scores on Role
Physical (r¼.59; p¼ .01), General Health (r¼.72;
p¼ .001), Vitality (r¼.74; p¼ .001) and Role Emotional
(r¼.55; p¼ .018) and poorer overall Physical (r¼.58;
p¼ .012) and Mental Component (r¼.52; p¼ .027)
scores. The findings indicate that greater AUCi and lesser
decline in cortisol level across the day to be associated with
poorer quality of life in PAH patients. A higher level of
cortisol at awakening and to a lesser extent, at þ30min,
appears beneficial for the physical and mental aspects of
PAH patients’ quality of life. The diurnal slope of cortisol
showed the greatest number of effects across five of the eight
QOL dimensions and in both physical and mental compo-
nent scores.
Fewer significant relationships were found between corti-
sone levels and QOL. However, a higher level of cortisone at
awakening was significantly associated with better QOL scores
for Physical Functioning (r¼ .53; p¼ .02) and General Health
(r¼ .56; p¼ .012) dimensions. A higher level of cortisone at
þ30 mins was significantly associated with better health scores
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on Physical Functioning (r¼ .51; p¼ .026) and Vitality
(r¼ .48; p¼ .04). No significant effects were found for evening
cortisone levels with QOL scores. A higher cortisone AUCg
was significantly associated with higher scores on Physical
Functioning (r¼ .50; p¼ .03) and Vitality (r¼ .46; p¼ .048)
dimensions, whereas a higher (flatter) cortisone slope value
was associated with poorer Social Functioning (r¼.66;
p¼ .02). No significant correlations were observed between
cortisone AUCi and QOL scores.
Our findings demonstrate ranges and patterning of diur-
nal cortisol/cortisone in this small sample of PAH patients
from a predominantly CHD cohort, to be comparable to
that observed in non clinical populations. QOL dimensions
as well as overall physical and mental health scores among
these PAH patients were below that of general population
norms, indicating a below average quality of life.
Interestingly, the QOL dimension of Bodily Pain, one
aspect of the condition that might frequently be used to
evaluate well-being, is the exception to this finding, scores
being comparative with population norms. Importantly,
despite this comparable range in cortisol/cortisone, indices
were significantly associated with both physical and mental
QOL in PAH; higher cortisol and cortisone at awakening
and þ30min were linked to better QOL across a number of
(a)
(b)
Fig. 1. Cortisol (a) and Cortisone (b) levels by patient participants; measured at awakening, 30min later and in the evening in people with PAH;
displays rise and fall, diurnal rhythm. Data show n¼ 18 participants (a) and n¼ 19 (b).
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physical health and vitality scores and higher evening corti-
sol and flatter diurnal decline of cortisol/cortisone with
poorer QOL across a range of physical and mental health
scores. The study was designed as an initial pilot and as such
has many limitations including the small sample size and
lack of a control group, restricting more robust statistical
comparisons. Furthermore, methodological limitations
include the use of a general health related QOL measure
rather than one specific to PAH. Attention to these and
other limitations is warranted in future work.
In conclusion, we suggest that cortisol and to a lesser
extent cortisone, provide potentially useful clinical indica-
tors of patient well-being in PAH. The current study is only
an indication of potential applications but if it were possible
to provide more frequent analysis of cortisol levels, even
with measurement of a continuous profile, or using sources
other than saliva, then we might be able to assess response
to medication and provide an objective health related meas-
ure of QOL independent of numerical cardio-pulmonary
assessments.
Acknowledgements
The authors would like to gratefully acknowledge all patients who
took part in the study and who contributed their time and effort in
providing the data.
Conflict of interest
The author(s) declare that there is no conflict of interest.
Funding
Funding was provided by the David Telling Trust (294) and the
Above and Beyond Charity of University Hospitals Bristol
Foundation Trust. The study was conducted alongside data col-
lected for the National Institute of Health Research (NIHR)
Research for Patient Benefit (Grant PB-PG-0711-25145) program.
The study was performed with NHS sponsorship and Research
Ethics Committee (REC) approval 12/SW/0264 with fully
informed consent of the patients taking part. It was conducted in
accordance with the Research Governance Framework for Health
and Social Care and Good Clinical Practice. The Cardio-vascular
theme of NIHR Bristol Biomedical Research Centre supported this
work. The funders played no role in the design of the study, in the
collection, analysis and interpretation of data, or in the decision to
submit the manuscript for publication. The views expressed in this
publication are those of the author(s) and not necessarily those of
the NHS, the National Institute for Health Research or the
Department of Health.
Contributorship
RT, FQ, JS, VG and JT-C made a substantial contribution to the
conceptualisation and design of the work; VG was responsible for
data acquisition; FQ and JS for assay analysis; JT-C for data ana-
lysis; and RT and JT-C for data interpretation. RT and JT-C
drafted the article; all authors revised the article and approved
the final version of the manuscript.
ORCID iD
JM Turner-Cobb https://orcid.org/0000-0002-3286-3244
References
1. Tulloh RMR, Garratt V, Tagney J, et al. A pilot randomised
controlled trial investigating a mindfulness-based stress reduc-
tion (MBSR) intervention in individuals with pulmonary arter-
ial hypertension (PAH): the PATHWAYS study. Pilot
Feasibility Stud 2018; 4: 78.
2. Lowe B, Grafe K, Ufer C, et al. Anxiety and depression in
patients with pulmonary hypertension. Psychosom Med 2004;
66: 831–836.
3. Harzheim D, Klose H, Pinado FP, et al. Anxiety and depres-
sion disorders in patients with pulmonary arterial hypertension
and chronic thromboembolic pulmonary hypertension. Respir
Res 2013; 14: 104.
4. McEwen BS. Protective and damaging effects of stress medi-
ators. N Engl J Med 1998; 338: 171–179.
5. Adam EK, Quinn ME, Tavernier R, et al. Diurnal cortisol
slopes and mental and physical health outcomes: a systematic
review and meta-analysis. Psychoneuroendocrinology 2017; 83:
25–41.
6. Fries E, Dettenborn L and Kirschbaum C. The cortisol awa-
kening response (CAR): facts and future directions. Int J
Psychophysiol 2009; 72: 67–73.
7. Pruessner JC, Kirschbaum C, Meinlschmid G, et al. Two for-
mulas for computation of the area under the curve represent
measures of total hormone concentration versus time-depen-
dent change. Psychoneuroendocrinology 2003; 28: 916–931.
8. Stalder T, Kirschbaum C, Kudielka BM, et al. Assessment of
the cortisol awakening response: expert consensus guidelines.
Psychoneuroendocrinology 2016; 63: 414–432.
9. Jenkinson C, Coulter A and Wright L. Short form 36 (SF36)
health survey questionnaire: normative data for adults of
working age. BMJ 1993; 306: 1437–1440.
10. Ceriotti F, Hinzmann R and Panteghini M. Reference inter-
vals: the way forward. Ann Clin Biochem 2009; 46: 8–17.
4 | Cortisol/cortisone levels and quality of life in PAH Tulloh et al.
